Waters downgraded by Evercore ISI with a new price target
$WAT
Biotechnology: Laboratory Analytical Instruments
Industrials
Evercore ISI downgraded Waters from Outperform to In-line and set a new price target of $270.00 from $285.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $355.00 → $415.00 | Hold → Buy | Jefferies |
| 8/28/2024 | $380.00 | Overweight | Wells Fargo |
| 8/1/2024 | $325.00 → $375.00 | Market Perform → Outperform | Leerink Partners |
| 6/3/2024 | $320.00 | Hold | Jefferies |
| 11/13/2023 | $270.00 → $230.00 | Equal Weight → Underweight | Barclays |
| 9/28/2023 | $280.00 | Mkt Perform | Bernstein |
| 7/31/2023 | $275.00 | Overweight → Equal Weight | Barclays |
| 7/31/2023 | $285.00 → $270.00 | Outperform → In-line | Evercore ISI |
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)
SC 13G - WATERS CORP /DE/ (0001000697) (Subject)
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
MILFORD, Mass., Oct. 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2024 financial results conference call live on Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least November 29th, 2024, at midnight Eastern Time. About Waters Corporation Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. W
Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currencyGAAP EPS of $2.40; earnings exceeded guidance with non-GAAP EPS of $2.63, led by strong operational performanceBeat driven by better-than-expected performance in China, as well as higher-than-expected M&A contribution to overall sales from WyattEx-China organic constant currency sales growth as expected across Pharma, Industrial, and Academic & Government end marketsFull-year outlook reflects the potential for a more gradual market improvement in the second half of the year than previously anticipatedSecond Quarter 2024 MILFORD, Mass., July 31, 2024 /PRNewswire/
Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currencyInstruments returned to growth; recurring revenue grew high single-digits in constant currencyAll reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & IndustrialGAAP EPS of $2.71 and non-GAAP EPS of $2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditionsRaised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarterThird Quarter 2024 MILFORD, Mass., Nov. 1, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced its financial
News Summary: Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders.Novel digestion enzymes deliver complete RNA sequence coveragei for more confident characterization, while new LC-MS-grade reagents increase sensitivity and improve detection accuracy of RNA components.iiNew waters_connect™ MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows that reduce data processing time over manual techniques, enabling routine monitoring of key product attributes.MILFORD, Mass., Oct. 10, 2024 /PRNew
News Summary: Easy-to-use, compact analyzer makes rheological insights more accessible to quality testing laboratories and material production facilities in batteries, pharmaceuticals, food, consumer goods, and other industries.Powered by RheoGuide™ Software, a streamlined, modern touchscreen user interface with built-in self-guided methods, workflows, and training applications to simplify rheological testing for all users.Superior analytical performance at an affordable price, with up to 2x better torque sensitivityi of comparable rheometers on the market.DETROIT, Oct. 8, 2024 /PRNewswire/ -- The Battery Show -- Waters Corporation (NYSE:WAT) today introduced the TA Instruments™ Discovery Co
8-K/A - WATERS CORP /DE/ (0001000697) (Filer)
10-Q - WATERS CORP /DE/ (0001000697) (Filer)
8-K - WATERS CORP /DE/ (0001000697) (Filer)
Evercore ISI Group analyst Vijay Kumar maintains Waters (NYSE:WAT) with a In-Line and lowers the price target from $320 to $300.
Across the recent three months, 6 analysts have shared their insights on Waters (NYSE:WAT), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 4 2 0 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 0 2M Ago 0 0 3 1 0 3M Ago 0 0 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $318.67, a high estimate of $358.00, and a low estimate of $275.00. Experiencing a 0.1% decline,
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Underweight and lowers the price target from $295 to $275.
Jefferies upgraded Waters from Hold to Buy and set a new price target of $415.00 from $355.00 previously
Wells Fargo initiated coverage of Waters with a rating of Overweight and set a new price target of $380.00
Leerink Partners upgraded Waters from Market Perform to Outperform and set a new price target of $375.00 from $325.00 previously
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4/A - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
4 - WATERS CORP /DE/ (0001000697) (Issuer)
MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for
Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,
Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company. "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointment